The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 28, 2017
Filed:
Mar. 24, 2016
Applicant:
Theaprin Pharmaceuticals Inc., Hauppauge, NY (US);
Inventors:
Harry G. Brittain, Milford, NJ (US);
Philip V. Felice, Smithtown, NY (US);
Assignee:
THEAPRIN PHARMACEUTICALS INC., Hauppauge, NY (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/12 (2006.01); A61K 47/48 (2006.01); A61K 31/704 (2006.01); A61K 31/13 (2006.01); A61K 31/137 (2006.01); A61K 31/192 (2006.01); A61K 31/198 (2006.01); A61K 31/277 (2006.01); A61K 31/4045 (2006.01); A61K 31/4164 (2006.01); A61K 31/4196 (2006.01); A61K 31/426 (2006.01); A61K 31/43 (2006.01); A61K 31/445 (2006.01); A61K 31/4745 (2006.01); A61K 31/48 (2006.01); A61K 31/496 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/522 (2006.01); A61K 31/536 (2006.01); A61K 31/545 (2006.01); A61K 31/546 (2006.01); A61K 31/549 (2006.01); A61K 31/573 (2006.01); A61K 31/635 (2006.01); A61K 31/7048 (2006.01); A61K 31/7072 (2006.01); A61K 47/18 (2017.01); A61K 31/4453 (2006.01);
U.S. Cl.
CPC ...
A61K 47/48038 (2013.01); A61K 31/13 (2013.01); A61K 31/137 (2013.01); A61K 31/192 (2013.01); A61K 31/198 (2013.01); A61K 31/277 (2013.01); A61K 31/4045 (2013.01); A61K 31/4164 (2013.01); A61K 31/4196 (2013.01); A61K 31/426 (2013.01); A61K 31/43 (2013.01); A61K 31/445 (2013.01); A61K 31/4453 (2013.01); A61K 31/4745 (2013.01); A61K 31/48 (2013.01); A61K 31/496 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/522 (2013.01); A61K 31/536 (2013.01); A61K 31/545 (2013.01); A61K 31/546 (2013.01); A61K 31/549 (2013.01); A61K 31/573 (2013.01); A61K 31/635 (2013.01); A61K 31/704 (2013.01); A61K 31/7048 (2013.01); A61K 31/7072 (2013.01); A61K 38/12 (2013.01); A61K 47/183 (2013.01);
Abstract
A method of making a water-soluble doxorubicin-theanine cocrystal composition. The method includes the steps of providing a quantity of doxorubicin, adding a quantity of a theanine enantiomer to the quantity of doxorubicin to form a mixture of the quantity of doxorubicin and the enantiomer of theanine, wetting the mixture, and grinding the mixture for a length of time sufficient to produce a dried crystalline mass.